drugset / Trial / NCT06953986
A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
RandomizedFactorialOpen-labelTreatment
Summary
Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.
Timeline
- Start
- 2025-12-20
- Primary completion
- 2026-11-20
- Completion
- 2027-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Esomeprazole | Small molecule | 40 mg | — |
| Subject | Vonoprazan | Other / unclassified | 10 mg | — |
| Subject | Vonoprazan | Other / unclassified | 20 mg | — |